News und Analysen
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
DGAP-Adhoc: Carl Zeiss Meditec achieves EBIT margin of 18.1% in fiscal year 2018/19
DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19
DGAP-Adhoc: Carl Zeiss Meditec erzielt EBIT-Marge von 18,1% im Geschäftsjahr 2018/19
EQS-News: Carl Zeiss Meditec closes first six months 2023/24 with a slight decline in revenue due to currency effects
EQS-News: Carl Zeiss Meditec closes first six months 2023/24 with a slight decline in revenue due to currency effects
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
EQS-News: Carl Zeiss Meditec achieves slight revenue growth in first quarter of 2023/24
EQS-Adhoc: Carl Zeiss Meditec AG agrees to launch share buyback program with volume of up to €150m
EQS-Adhoc: Carl Zeiss Meditec AG agrees to launch share buyback program with volume of up to €150m
EQS-News: U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS
EQS-News: U.S. FDA Approves the VISUMAX 800 with SMILE pro software from ZEISS
EQS-News: Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)
EQS-News: Carl Zeiss Meditec AG announces agreement to acquire Dutch Ophthalmic Research Center (D.O.R.C.)
EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.
EQS-Adhoc: Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C.
EQS-News: Carl Zeiss Meditec increased revenue in fiscal year 2022/23 by around 10 percent
EQS-News: Carl Zeiss Meditec increased revenue in fiscal year 2022/23 by around 10 percent
EQS-News: Carl Zeiss Meditec achieves further strong revenue growth after nine months of fiscal year 2022/23 with continued high strategic investments
EQS-News: Carl Zeiss Meditec achieves further strong revenue growth after nine months of fiscal year 2022/23 with continued high strategic investments
EQS-News: Carl Zeiss Meditec achieves double-digit growth in first half year of 2022/23 with declining earnings
EQS-News: Carl Zeiss Meditec achieves double-digit growth in first half year of 2022/23 with declining earnings
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
EQS-Adhoc: Forecast for fiscal year 2022/23 refined – Targeting widened and reduced range for EBIT margin – Further growth with reduced earnings in first half year of 2022/23
EQS-News: Carl Zeiss Meditec achieves further revenue growth in Q1 2022/23 – Orders on hand remain high
EQS-News: Carl Zeiss Meditec achieves further revenue growth in Q1 2022/23 – Orders on hand remain high
EQS-News: Carl Zeiss Meditec remains on growth course in fiscal year 2021/22
EQS-News: Carl Zeiss Meditec remains on growth course in fiscal year 2021/22
DGAP-News: Carl Zeiss Meditec achieves further significant growth in revenue and order intake after nine months of 2021/22
DGAP-News: Carl Zeiss Meditec achieves further significant growth in revenue and order intake after nine months of 2021/22
DGAP-News: Carl Zeiss Meditec achieves further significant growth in revenue and order intake in first half 2021/22
DGAP-News: Carl Zeiss Meditec achieves further significant growth in revenue and order intake in first half 2021/22
DGAP-News: Carl Zeiss Meditec acquires two manufacturers of surgical instruments
DGAP-News: Carl Zeiss Meditec acquires two manufacturers of surgical instruments
Eckert & Ziegler: Charttechnik deutet Kursexplosion an!
Ein explosives charttechnisches Setup finden Trader zurzeit bei der Aktie von Eckert & Ziegler (WKN: 565970) vor. Verhält sich die Aktie regelkonform, winkt hier ein Kurssprung!
So konnte die Aktie
Eckert & Ziegler unter Abgabedruck: Die Alternative?!
Die Aktie von Eckert & Ziegler (WKN: 565970) steht heute unter Abgabedruck, nachdem das deutsche Vorzeige-Medizintechnikunternehmen seine aktuellen Quartalszahlen vorgelegt hat. Denn diese fielen
Sartorius: Unternehmen profitiert von der Corona-Krise
Ein absoluter Highflyer am deutschen Aktienmarkt ist schon seit vielen Jahren die Vorzugsaktie des Göttinger Laborausrüsters Sartorius (WKN: 716563). Dies ist umso erstaunlicher, da noch zu Neuer
EQS-News: Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
EQS-News: Eckert & Ziegler with significant increase in sales (+17%) and adjusted EBIT (+41%) in Q1. Forecast 2024 confirmed.
EQS-Adhoc: Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
EQS-Adhoc: Eckert & Ziegler: Q1 with Significant Increase in Sales and Earnings Compared to Previous year. 2024 Annual Forecast Confirmed.
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Continues on Growth Path after Successful Financial Year 2023
EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
EQS-News: Eckert & Ziegler Receives MDR Certification for Prostate Seeds, Paving the Way for Long-term Supply
EQS-Adhoc: Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.
EQS-Adhoc: Eckert & Ziegler Reduces Dividend to Finance Future Investments. Earnings Growth Expected for 2024.